Theravance Announces Positive Results from a Phase 2a Study of its LAMA Candidate, TD-4208, for the Treatment of COPD
Theravance Announces Positive Results from a Phase 2a Study of its LAMA Candidate, TD-4208, for the Treatment of COPD
Nov 14, 2011